Author/Authors :
Çelik, Fatmanur Çanakkale Onsekiz Mart University Faculty of Medicine - Department of Nuclear Medicine - Çanakkale, Turkey , Tan, Yusuf Ziya Çanakkale Onsekiz Mart University Faculty of Medicine - Department of Nuclear Medicine - Çanakkale, Turkey , Özdemir, Semra Çanakkale Onsekiz Mart University Faculty of Medicine - Department of Nuclear Medicine - Çanakkale, Turkey , Sılan, Fatma Çanakkale Onsekiz Mart University Faculty of Medicine - Department of Medical Genetic - Çanakkale, Turkey
Abstract :
The aim of this study was to compare the quantitative value of standardized uptake value (SUV) SUVmax obtained from F-18 FDG positron emission tomography/computed tomography (PET/CT) imaging of oncology patients with the cell-free DNA (cfDNA) amounts measured in plasma of patients and thus investigate if cfDNA is a significant marker to identify the presence of malignancy in the early period.Methods: A total of 184 patients were included in the study. The clinical, histopathologic, laboratory and treatment parameters were extracted from patient files. SUVmax and cfDNA quantities were assessed.Results: There was no statistically significant difference in plasma cfDNA values between patient and control groups. The comparison of SUVmax and cfDNA values in the study showed that there was a weak correlation between SUVmax and cfDNA. There was a significant difference between tumor size and SUVmax values. However, there was no statistically significant difference between tumor size and cfDNA.Conclusion: cfDNA measurements in the blood as a screening test have provided hope for early diagnosis and monitoring of cancer patients. Comparison of cfDNA levels obtained from plasma and quantitative parameters from PET/CT images of oncology patients in detailed advanced studies with larger patient series are required.
